1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

IGBA Kicks Off Biosimilars Week With New White Paper

Urges Regulators To Adopt Principles Of Revised WHO Biosimilars Guideline

 
• By Dave Wallace

The IGBA has kicked off its third annual global biosimilars week awareness campaign with the release of a white paper that urges stakeholders to recognize and adopt recommendations from the WHO’s latest revised biosimilars guideline.

World Map Syringe Vial
The IGBA’s third annual global biosimilars week runs from 14-18 November • Source: Shutterstock

A third global biosimilars week awareness campaign running from 14-18 November has been launched by the International Generic and Biosimilar Medicines Association, with the IGBA also taking this opportunity to launch a new white paper that urges the uptake of recommendations from the World Health Organization’s latest revised biosimilars guideline from earlier this year.

“In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients,” the association said, with the third annual iteration of the campaign supported by

More from Biosimilars

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

More from Products

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”